Research programme: anti-methamphetamine therapies - InterveXion
Alternative Names: ICKLH-SMO9; PCP-mAbLatest Information Update: 28 May 2020
At a glance
- Originator University of Arkansas for Medical Sciences
- Developer InterveXion Therapeutics; University of Arkansas for Medical Sciences
- Class Conjugate vaccines; Monoclonal antibodies; Vaccines
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Substance-related disorders
Most Recent Events
- 28 May 2020 No recent reports of development identified for preclinical development in Substance-related disorders(Prevention) in USA (IV, Injection)
- 04 Nov 2017 No recent reports of development identified for preclinical development in Substance-related disorders in USA (Parenteral)
- 05 Apr 2016 Preclinical trials in Substance-related disorders (Prevention) in USA (Parenteral) (InterveXion Therapeutics Pipeline; April 2016), prior to April 2016